# Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis

> **NCT05234580** · PHASE2 · COMPLETED · sponsor: **Anhui Palo Alto Pharmaceuticals, Inc.** · enrollment: 204 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** PA9159 nasal spray solution, 10 μg once daily for 14 days
- **DRUG:** PA9159 nasal spray solution, 20 μg once daily for 14 days
- **DRUG:** PA9159 nasal spray solution, 40 μg once daily for 14 days
- **DRUG:** Placebo nasal spray solution without PA9159, once daily for 14 days

## Key facts

- **NCT ID:** NCT05234580
- **Lead sponsor:** Anhui Palo Alto Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-15
- **Primary completion:** 2022-10-10
- **Final completion:** 2022-12-25
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2023-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05234580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05234580, "Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05234580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*